Description
Elsevier Integrated Behavioral Health in Pediatric Practice An Issue of Pediatric Clinics of North America 1st Edition by Apple, Roger W.
In this issue of Pediatric Clinics, Guest Editors Roger W. Apple, Cheryl A. Dickson, and Maria Demma Cabral bring their considerable expertise to the topic of Integrated Behavioral Health in Pediatric Practice. Top experts in the field cover key topics such as the need for IBH in pediatric primary care, IBH in pediatric residency clinics, the past and current role of pediatric psychologists in IBH within medical subspecialties, and more. Provides concise and comprehensive coverage of the issues physicians face every day.Presents the latest information on a timely, focused topic under the leadership of experienced editors in the field.Contains 15 relevant, practice-oriented topics including definitions and contexts; history of pediatrics and the development of IBH; common behavioral concerns; BHC roles and responsibilities; and more. Potential Relevance of B-cell Maturation Pathways in Defining the Cell(s) of Origin for Chronic Lymphocytic LeukemiaThe Significance of B-cell Receptor Stereotypy in Chronic Lymphocytic Leukemia: Biological and Clinical ImplicationsPrognostic and Predictive Implications of Cytogenetics and GenomicsGenomics of Resistance to Targeted TherapiesFirst-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and BeyondBruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond IbrutinibShould Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase InhibitorsThe Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic LeukemiaCan Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond